APBB2: A Promising Drug Target and Biomarker for Alzheimer's Disease

Target Name: APBB2

NCBI ID: G323

APBB2

Other Name(s): Amyloid beta precursor protein binding family B member 2 (isoform b) | Amyloid beta precursor protein binding family B member 2, transcript variant 2 | protein Fe65-like 1 | Amyloid-beta (A4) precursor protein-binding family B member 2 | Fe65-like protein | Amyloid beta precursor protein binding family B member 2, transcript variant 4 | Fe65-like 1 | FE65L1 | APBB2 variant 4 | Amyloid beta precursor protein binding family B member 2 | FE65L | APBB2 variant 3 | Amyloid beta precursor protein binding family B member 2, transcript variant 3 | Amyloid beta A4 precursor protein-binding family B member 2 | Amyloid beta precursor protein binding family B member 2 (isoform c) | Protein Fe65-like 1 | Amyloid-beta A4 precursor protein-binding family B member 2 | APBB2 variant 2 | APBB2_HUMAN | Amyloid beta A4 precursor protein-binding family B member 2 (APBB2) | Amyloid beta precursor protein binding family B member 2 (isoform d) | amyloid beta precursor protein binding family B member 2

APBB2: A Promising Drug Target and Biomarker for Alzheimer's Disease

Alzheimer's disease is a debilitating neurological disorder that affects millions of people worldwide, primarily as a result of the accumulation of beta-amyloid plaques and neurofibrillary tangles in the brain. The most common cause of Alzheimer's disease is the neurodegeneration associated with aging (NAIA), which is characterized by the progressive accumulation of dysfunctional proteins, including beta-amyloid plaques and neurofibrillary tangles. The development of these hallmark proteins is thought to initiate a cascade of cellular and molecular events that ultimately lead to the degenerative changes observed in Alzheimer's disease.

The APBB2 protein, a member of the Amyloid beta precursor protein (APP) binding family B, is of particular interest as a potential drug target and biomarker for Alzheimer's disease. In this article, we will discuss the biology and pathology of Alzheimer's disease, the APBB2 protein, and its potential as a drug target.

Biography of APBB2

The APBB2 protein is a 21-kDa transmembrane protein that is expressed in various tissues and cell types, including brain, heart, and liver. It is a member of the APP binding family B, which includes several related proteins, including APBB1, APP1, and APP2. The APBB2 protein is characterized by a N-terminus that contains a unique farnesylated cysteine residue, which is thought to play a crucial role in its stability and localization to the endoplasmic reticulum (ER).

Function and localization of APBB2

The function of APBB2 is not well understood, but its localization to the ER and its association with the endoplasmic reticulum-associated degradation (ERAD) pathway suggest that it may be involved in the delivery and processing of beta-amyloid peptides from the axon terminal vesicles to the ER.

In addition to its localization to the ER, APBB2 is also known to be involved in the regulation of the cytoskeleton and cell adhesion. It has been shown to play a role in the regulation of microtubule dynamics and the assembly and disassembly of microtubules. Furthermore, it has been shown to be involved in the regulation of cell adhesion, which is critical for the maintenance of tissue structure and the development of various diseases, including Alzheimer's disease.

Potential drug targets and biomarkers

The APBB2 protein is a potential drug target for Alzheimer's disease due to its involvement in the regulation of beta-amyloid peptide delivery to the ER. Several studies have shown that inhibiting the activity of APBB2, either alone or in combination with other therapeutic approaches, can reduce the formation of beta-amyloid plaques and improve cognitive function in animal models of Alzheimer's disease.

In addition to its potential as a drug target, APBB2 has also been shown to be a potential biomarker for Alzheimer's disease. The accumulation of beta-amyloid peptides in the brain is a well-established biomarker for Alzheimer's disease, but the clearance of beta-amyloid peptides from the axon terminal vesicles to the ER is a new and promising biomarker. The accumulation of beta-amyloid peptides in the ER is thought to be a critical step in the formation of beta-amyloid plaques, and therefore, the clearance of these peptides to the ER may be a useful biomarker for the diagnosis and treatment of Alzheimer's disease.

Conclusion

In conclusion, the APBB2 protein is a unique and promising drug target and biomarker for Alzheimer's disease. Its localization to the ER and its involvement in the regulation of beta-amyloid peptide delivery to the ER suggest that it may play a critical role in the development and progression of Alzheimer's disease. The potential use of

Protein Name: Amyloid Beta Precursor Protein Binding Family B Member 2

Functions: Plays a role in the maintenance of lens transparency, and may also play a role in muscle cell strength (By similarity). Involved in hippocampal neurite branching and neuromuscular junction formation, as a result plays a role in spatial memory functioning (By similarity). Activates transcription of APP (PubMed:14527950)

The "APBB2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about APBB2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets